Chugai Pharmaceutical Co., Ltd. (CHGCY)
Stock Price: $22.43 USD
-0.92 (-3.94%)
Updated Feb 26, 2021 3:59 PM EST - Market closed
| Market Cap | 73.54B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 559.69M |
| EPS (ttm) | 2.85 |
| PE Ratio | 7.88 |
| Forward PE | 31.65 |
| Dividend | $0.58 |
| Dividend Yield | 2.59% |
| Trading Day | February 26 |
| Last Price | $22.43 |
| Previous Close | $23.35 |
| Change ($) | -0.92 |
| Change (%) | -3.94% |
| Day's Open | 23.07 |
| Day's Range | 22.28 - 23.07 |
| Day's Volume | 45,518 |
| 52-Week Range | 15.3333 - 29.32 |
News
There are no news available yet.
About CHGCY
Chugai Pharmaceutical Company, together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellC... [Read more...]
| Industry Drug Manufacturers-General | Founded 1925 |
| CEO Tatsuro Kosaka | Employees 7,555 |
| Stock Exchange OTCMKTS | Ticker Symbol CHGCY |